CD47 and hematopoietic and lymphoid system neoplasm: Since CD47 is upregulated in both solid and hematological tumors and such overexpression is correlated with poor patient survival or poor response to therapy, several CD47-SIRPα antagonists were developed and are currently active in clinical trials [184].